Key Insights

Highlights

Success Rate

70% trial completion

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 27/100

Termination Rate

15.0%

3 terminated out of 20 trials

Success Rate

70.0%

-16.6% vs benchmark

Late-Stage Pipeline

30%

6 trials in Phase 3/4

Results Transparency

143%

10 of 7 completed with results

Key Signals

10 with results70% success

Data Visualizations

Phase Distribution

18Total
P 1 (5)
P 2 (7)
P 3 (4)
P 4 (2)

Trial Status

Completed7
Recruiting5
Active Not Recruiting4
Terminated3
Not Yet Recruiting1

Trial Success Rate

70.0%

Benchmark: 86.6%

Based on 7 completed trials

Clinical Trials (20)

Showing 20 of 20 trials
NCT07832747Phase 2Not Yet RecruitingPrimary

A Study of DCC-3014 to Evaluate the Efficacy, Safety, and Pharmacokinetics in Subjects With TGCT

NCT07499362Phase 2RecruitingPrimary

Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)

NCT07075471RecruitingPrimary

MOVE: Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib

NCT04488822Phase 3Active Not RecruitingPrimary

A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT

NCT03069469Phase 1Active Not Recruiting

Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor

NCT04703322Phase 2CompletedPrimary

A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan

NCT05804045Phase 3Active Not RecruitingPrimary

Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)

NCT05059262Phase 3Active Not RecruitingPrimary

Study of Vimseltinib for Tenosynovial Giant Cell Tumor

NCT04192344Phase 1Recruiting

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor

NCT01207492Phase 2Completed

Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor

NCT07315841Phase 4RecruitingPrimary

Accuracy of Indocyanine Green (ICG) Fluorescence Imaging in Tenosynovial Giant Cell Tumor Surgery

NCT04635111Recruiting

A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment

NCT04526704Phase 4CompletedPrimary

Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib

NCT05349643Phase 2Completed

A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT

NCT04731675Phase 2CompletedPrimary

An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee

NCT04938180Phase 2TerminatedPrimary

A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients

NCT02371369Phase 3Completed

Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)

NCT02471716Phase 1Completed

Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor

NCT01804530Phase 1Terminated

Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors

NCT02673736Phase 1Terminated

A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor

Showing all 20 trials

Research Network

Activity Timeline